GSK to Invest More Than $1B in Manufacturing, R&D
The commitment is part of a five-year, $30 billion capital deployment plan across the nation.
GSK will commit $1.2 billion to support its advanced production facilities and digital technologies. This plan includes the construction of a new plant in Upper Merion, Pa., set to produce medicine for respiratory diseases and cancer. Shovels are slated to hit the ground next year.
The capital will also serve to improve its existing manufacturing campuses across Pennsylvania, North Carolina, Maryland and Montana through AI implementation. Additionally, the funds are set to expand GSK’s auto-injector device assembly and capabilities.
This pledge is part of the company’s five-year strategy to invest $30 billion throughout the U.S. in manufacturing and R&D, which will also includes plans to strengthen its supply chain.
READ ALSO: Fed Makes 1st Rate Cut of 2025, More to Come
GSK already has another $800 million Pennsylvania expansion in the works, which will double the capacity of its existing campus at the Marietta, Penn., site. The pharma company broke ground on the project last year, aiming for a staggered completion in 2027 and 2028.
U.S. biomanufacturing investment ramps up
As trade policy uncertainty continues permeating the market, pharma companies began adjusting their U.S. strategies, with GSK being the latest firm to pledge billions in investment across the nation.
Eli Lilly vowed to invest $27 billion by 2030 with plans calling for the development of four manufacturing plants. Just this week, it revealed one of these projects, a $5 billion bioconjugate production facility in Richmond, Va.
Two months ago, AstraZeneca pledged to invest $50 billion across the U.S. by 2030. Its roadmap also includes, among other developments, a drug substance facility in Virginia that would leverage AI automation to optimize production. That project would be the company’s largest single manufacturing investment ever recorded.
In April, Roche revealed its plans to commit $50 billion across the next five years to strengthen its manufacturing and R&D campuses. One month later, it set out to invest $550 million to expand in Indianapolis and commit $700 million for a new project in North Carolina.
You must be logged in to post a comment.